CHINESE国产HD中国熟女,大学生扒开粉嫩喷白浆,FREEXXXX性特大另类,精品多毛少妇人妻av免费久久

Born in 1974, Dr. Leng is a senior engineer and scientist. He graduated from Jilin Institute of Chemical Technology in 1997 with a bachelor's degree in fine chemical engineering, and graduated from Liaoning Normal University in 2013 with a doctoral degree in cell biology. He joined the company in 1997 and was engaged in the research of protein biologics and the commercialization of research results. Dr. Leng received the second prize of the National Science and Technology Progress Award, and is a beneficiary of the special allowance granted by the State Council. He is also recognized as a national model worker, a national outstanding science and technology worker, a senior management expert of Jilin Province, and a Changbai Mountain scholar. He used to serve as a Director and a Deputy General Manager of the company, and now he leads the company as the Chairman and General Manager.

Born in 1988, Mr. Li graduated from the Fresenius University of Applied Sciences in Germany in 2016 with a bachelor's degree in business management. He worked for Ford Industries Import and Export GmbH from 2012, and joined Dongbao Enterprise Group in February 2016. He used to serve as Secretary to the Chairman, Assistant to the Chairman, and Deputy General Manager of the group. Since March 2019, Mr. Li has been the Chairman and General Manager of Dongbao Enterprise Group. He is also a Director of the company.

Born in 1976, Mr. Zhang earned his bachelor's degree in clinical medicine from Tongji Medical University in 1999 and graduated from Renmin University of China in 2011 with a bachelor's degree in business administration. He worked as a Pharmaceutical Sales Representative of Federal Pharmaceuticals Beijing office from 2000-2002, a Medical Specialist of Eli Lilly and Company from 2002-2005, and served as Regional Manager and Deputy General Manager after joining the company in 2005. Mr. Zhang is now a Director and a Deputy General Manager (Sales) of the company.

Born in 1974, Mr. Zhang graduated from Harbin University of Commerce in July 1998 with a bachelor's degree in traditional Chinese pharmacy. He worked as a TCM Pharmacist at Beijing Daxing District Hospital of Traditional Chinese Medicine from July 1998 to February 2002, and a Pharmaceutical Sales Representative of Eli Lilly Asia Inc (Beijing office) from February 2002 to March 2004. He joined the company in 2004, and served as a Regional Manager and a Deputy General Manager. Mr. Zhang is now a Director and a Deputy General Manager (Sales) of the company.

Born in 1983, Mr. Wang graduated from Shanghai Jiao Tong University with a bachelor's degree, and has been a Managing Director of DCP Investments since 2017. He served as an Executive Director at Kohlberg Kravis Roberts & Co. L.P. (Greater China) from 2011 to 2016 and received the KKR Founder's Special Award in 2014 for his valuable contributions to KKR Asia. He served as a Senior Investment Manager at Orchid Asia Group from 2007 to 2011, and a Business Analysis Consultant at McKinsey & Company from 2005 to 2007. Mr. Wang has been dedicated to investment business in healthcare and consumer goods industries for more than ten years, with total investment reaching over USD 1 billion. He initiated and led the investment transactions in Tonghua Dongbao, American-Sino Healthcare Shanghai, Venus MedTech Hangzhou Inc (2500.HK), Qingdao Haier (600690.SH), China Cord Blood Corporation (NYSE:CO), Sinopharm Holding (China) Finance Leasing, Joy Healthcare, Ascendum Capital, Broncus, China Outfitters Holdings (1146.HK), Sino-Ocean Group Holdings (3377.HK), etc. He is now a Supervisor at Venus MedTech Hangzhou Inc, a Director at China Outfitters Holdings, a Director at Sinopharm Holding (China) Finance Leasing, and a member of the Hong Kong Independent Non-Executive Director Association (HKiNEDA). He is also a Director of the company.

Born in 1984, Mr. Ju acquired his master's degree from the China Foreign Affairs University. He has served as an Executive Director at DCP Investments since April 2018, mainly responsible for investment in the healthcare industry. He once led investment in Tonghua Dongbao and American-Sino Healthcare Shanghai. Mr. Ju worked at CITIC Capital Holdings Limited from May 2011 to March 2018, where his previous jobs in the private equity business unit included Investment Manager, Senior Manager, Vice President, and Director. From July 2009 to April 2011, he worked at Lazard Business Consulting (Beijing). He is also a Director of the company.

Born in 1967, Xu Dai is a member of the Communist Party of China and a Doctor of Law. He is a professor and doctoral advisor at the School of Law of Jilin University, and a visiting scholar at Duke University in the United States and at the Faculty of Law, the University of Hong Kong. Prof. Xu is also a member of the National JM Education Steering Committee, the executive director of the Chinese Association of Criminal Law, the vice president of the Chinese Society of Criminology, a member of the Chinese Branch of the International Association of Penal Law, the vice president for criminal law research of Jilin Law Society, the executive vice president and secretary general for crime prevention research of Jilin Law Society, and a member of the Judges and Prosecutors Selection Committee of Jilin Province. He won the 2nd Award for "Top Ten Outstanding Young and Middle-aged Jurists in Jilin Province", and was among the sixteenth batch of experts with allowances granted by the Jilin Provincial Government. His research interests focus on cross-cutting studies of civil and criminal laws and corporate compliance. He has published many papers including one titled "The Dilemma and Solution Concerning the Implementation of Criminal Responsibility Associated with Organizational Crimes." With these papers, he has won the third prize of the Outstanding Achievement Award granted by the China Law Society, and the first prize of the Outstanding Achievement Award for Social Sciences of Jilin Province (twice). Now, he serves as an independent director of Tonghua Dongbao.

Born in 1966, Ms. Bi is a Senior Accountant, and a Certified Public Accountant. She graduated from the Faculty of Accounting of Jilin Finance and Trade College (now Jilin University of Finance and Economics) in 1989 with a bachelor's degree in economics, and serves as Chief Accountant of Jilin Xinyuan Accounting Firm. Ms. Bi is also an Independent Director of the company.

Born in 1967, with a Ph.D. in Physical Chemistry, Xu Li is a professor at the School of Life Sciences of Jilin University, a senior research scholar at Arizona State University and George Washington University in the United States, and a visiting professor at Kansai Gakuin University in Japan, and a visiting scholar at INRA Institute in France. His research interests focus on molecular enzymology and targeted drug delivery. He has undertaken many research projects, including one project under the National High-tech R&D Program (863 Program), four projects funded by the National Natural Science Foundation of China, one project supported by the National Administration of Traditional Chinese Medicine, and multiple major projects supported by Jilin Provincial Department of Science and Technology. He has published more than 60 articles in famous journals such as Biosensors & Bioelectronics, ACS Applied Materials & Interfaces, and the Journal of the American Chemical Society. He has won four second prizes of the Natural Science Award of Jilin Province and has been issued four patents. Now, he serves as an independent director of Tonghua Dongbao.